[ad_1]
“I firmly hope that the vaccine will be in Bulgaria on New Year’s Eve. The company is extremely responsible and every effort is made for the complete safety of the preparation, which must be registered by the European Medicines Agency.
Bulgaria has an agreement to receive 2.5 million drugs, mainly for risk groups, with concomitant diseases and the elderly, “said Penkov. When asked if vaccine trials had stopped in Brazil after the death of a 28-year-old man said there was already evidence that the man was from the placebo group.
On August 28, the EC announced that it had signed a contract on behalf of member states with the British pharmaceutical giant AstraZeneca for the supply of at least 300 million doses of its vaccine against the novel coronavirus. The agreement provides for the option to purchase an additional 100 million doses to be distributed according to the population of the member states.
A Sun post today (see below) announced that health authorities in the UK are preparing to release the AstraZeneca vaccine to the public shortly after Christmas. The estimated price of a vaccine dose for EU countries is 1.78 euros.
Due to the increasing number of coronavirus infections in our country, the Ministry of Health has recommended that all hospitals create rooms in which to isolate people until it is determined whether the patient has a coronavirus or not.
All hospitals must open compartments for COVID-19. If they don’t, their NHIF funding will be suspended. This will be recorded in next year’s budget.
Bristol University Study: Oxford Serum ‘Works Perfectly’ Against Infections
The coronavirus vaccine, developed by the University of Oxford and AstraZeneca, for which the European Commission has signed a contract to supply 300 million doses, “works perfectly” and generates strong immunity. That’s according to a study by researchers at the University of Bristol, cited in the English edition of The Sun.
Currently, trials of the drug are in phase 3, when it is injected into thousands of volunteers. Upon successful completion of this phase, your approval for bulk application, the last stage of development, follows.
So far, the preparation has successfully passed the first three phases (see table). It is currently in phase III and has been injected into 18,000 volunteers in the United States, United Kingdom, Brazil and South Africa. It is injected into the body in two doses.
Previous tests showed that the drug successfully and safely elicited an immune response in volunteers. Vaccines typically use a weakened virus or small amounts, but the innovative preparation, developed at Oxford, causes the body to create a certain amount of the virus on its own.
Researchers at the University of Bristol believe that this new technique works successfully against the coronavirus.
“We now know that the vaccine is doing everything we expected, and that’s good news in our fight against the disease,” said Dr Matthews from the University of Bristol School of Cellular and Molecular Medicine, who led the team. .
The UK health authorities announced a few days ago that they are preparing to launch the vaccine for the population shortly after Christmas.
Chronology
One of the volunteers in the vaccine samples, Brazilian Dr. Joao Pedro Feitoza, died of complications from the coronavirus while participating in tests of the drug. It is believed that the doctor did not receive a dose of the vaccine, but instead was injected with a safe placebo, as provided by the sample technology.
Last month, AstraZeneca halted a pilot study of the vaccine after a UK volunteer was admitted to hospital with a suspected neurological complication. Two days later, after investigators investigated exactly what happened to the volunteer, testing was resumed in the UK.
It is assumed that the countries of the European Union will receive this vaccine between December 2020 and June 2021, and the distribution will be according to a fixed percentage of the population.
Currently, 48 different coronavirus vaccines are undergoing clinical trials around the world, 11 of which are in their final stages. Experts are convinced that there will be a vaccine soon, and not just one.
It remains to be seen how long the protective effect of the vaccine against infection will last.
Rules in the capital
An algorithm for COVID-19 launched in Sofia schools
The capital’s schools and kindergartens already have a rapid reaction algorithm in place in case a child, student or staff member is infected with COVID-19. This was announced on Facebook by the mayor of Sofia Yordanka Fandakova.
The rules were drawn up by the Sofia Health Inspectorate and adopted by decision of the Sofia Operations Headquarters. The aim is to provide the principals of kindergartens, kindergartens and schools with clear steps to follow.
Such an algorithm is also being developed for heads of social households, explains Fandakova. According to the rules, a child or student who tests positive for COVID-19 is immediately released and removed from the educational institution for home quarantine.
People who have been in prolonged contact with an infected student / child are released and placed in home quarantine: 2 days before the start of the complaints or 2 days before the collection of samples for the PCR test in asymptomatic carriers.
Sofia Mayor Yordanka Fandakova recalls that police teams and the Sofia Inspectorate are beginning to intensify inspections of nightclubs and discos. The objective is to control the reduced capacity requirement: one person for every 2 m2 of commercial area of the site.
As of Monday, October 26, aid for the purchase of basic necessities for the elderly, single and sick, will be renewed. “The aim of our initiative is to reduce the need for older people to go out, as the employees of the municipality’s emergency department buy instead of them,” says Fandakova.
Zoya Paunova, CEO of AstraZeneca-Bulgaria: The contract foresees that deliveries will start at the end of the year.
The agreement between AstraZeneca and the EC, which builds on the agreement of the EU Inclusive Vaccine Alliance and supports the production of 400 million doses of the potential vaccine at the University of Oxford, expects deliveries to begin late of year.
AstraZeneca is committed to working with governments and key partners to develop and obtain regulatory approval for an effective vaccine as soon as possible.
Associate Professor Andrey Chorbanov, BAS Immunologist: Just because the body reacts does not mean that you will be protected
If the AstraZeneca vaccine is in Bulgaria for up to 3-4 months, this would mean extremely short and cost-effective procedures. The three to four month period is unrealistic for any of the vaccines that are in clinical trials.
Theoretically, the vaccine could be launched next fall, but companies are in a rush to sign contracts with countries.
In fact, getting involved in a clinical trial in its third or fourth phase is not a problem, but pharmaceutical companies determine which groups of people should be tested.
The spectrum must be very broad to ensure that there are no side effects and to show that it is effective. So far, the effect has not been tested in any of the vaccines. What has been done so far is to show that the drugs elicit an immune response and are not harmful. And the real test is virus infection on a large scale.
This is done after it has been proven that there are no specific toxicities or side effects and the vaccine has been proven to cause something in the body. But just because the body reacts does not mean that it will be protected from this vaccine.
Academician Bogdan Petrunov, Immunologist: It is not serious to make predictions for the registry
Much depends on the EU control authorities when they will allow the registration of the vaccine. There is currently a problem in Brazil because a 28-year-old man has died. What caused his death is checked: the vaccine or the disease itself.
Before there is a decision from the Center for Disease Control in Europe, there is no way to import a COVID-19 vaccine into our country. The European Medicines Agency cannot authorize the use of the vaccine until it has completed the clinical trial procedure.
At the moment, it is not serious to make predictions regarding accelerated registration times. We have to be very careful what we say. As far as I know, our Association for Clinical Trials intends to include Bulgaria in the trials of a vaccine against COVID-19, but I don’t know how far they have gone.
[ad_2]
